

Aidan Hollis

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/59860/aidan-hollis-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

63
papers

968
citations

17
h-index

30
g-index

66
ext. papers

1,193
ext. citations

5
avg, IF

4.86
L-index

#	Paper	IF	Citations
63	The private versus public contribution to the biomedical literature during the COVID-19, Ebola, H1N1, and Zika public health emergencies. <i>PLoS ONE</i> , 2021 , 16, e0258013	3.7	0
62	Market concentration of new antibiotic sales. <i>Journal of Antibiotics</i> , 2021 , 74, 421-423	3.7	2
61	The economic theory of cost-effectiveness thresholds in health: Domestic and international implications. <i>Health Economics (United Kingdom)</i> , 2021 , 30, 1139-1151	2.4	
60	Pre-market development times for innovative vaccines - to what extent are the COVID-19 vaccines outliers?. <i>Clinical Infectious Diseases</i> , 2021 ,	11.6	1
59	Attitudes, behaviours and barriers to public health measures for COVID-19: a survey to inform public health messaging. <i>BMC Public Health</i> , 2021 , 21, 765	4.1	12
58	Reimagining Pharmaceutical Market Exclusivities: Should the Duration of Guaranteed Monopoly Periods Be Value Based?. <i>Value in Health</i> , 2021 , 24, 1328-1334	3.3	3
57	Repurposing existing drugs for new uses: a cohort study of the frequency of FDA-granted new indication exclusivities since 1997. <i>Journal of Pharmaceutical Policy and Practice</i> , 2021 , 14, 3	3.2	12
56	Patient income and health innovation. <i>Health Economics (United Kingdom)</i> , 2020 , 29, 1795-1803	2.4	1
55	Industry incentives and antibiotic resistance: an introduction to the antibiotic susceptibility bonus. <i>Journal of Antibiotics</i> , 2020 , 73, 421-428	3.7	25
54	Impact of isolation precautions on quality of life: a meta-analysis. <i>Journal of Hospital Infection</i> , 2020 , 105, 35-42	6.9	39
53	Global clinical trial mobilization for COVID-19: higher, faster, stronger. <i>Drug Discovery Today</i> , 2020 , 25, 1801-1806	8.8	1
52	Factors associated with drug shortages in Canada: a retrospective cohort study. <i>CMAJ Open</i> , 2020 , 8, E535-E544	2.5	1
51	Estimating the clinical cost of drug development for orphan versus non-orphan drugs. <i>Orphanet Journal of Rare Diseases</i> , 2019 , 14, 12	4.2	41
50	The impact of pharmaceutical rebates on patients' drug expenditures. <i>Cmaj</i> , 2019 , 191, E308-E312	3.5	1
49	Orphan Drug Pricing and Costs: A Case Study of Kalydeco and Orkambi. <i>Healthcare Policy</i> , 2019 , 15, 70-80.	1	5
48	How will recent trade agreements that extend market protections for brand-name prescription pharmaceuticals impact expenditures and generic access in Canada?. <i>Health Policy</i> , 2019 , 123, 1251-1258 ^{3,2}		3
47	In defense of Canada's drug plan managers. <i>Cmaj</i> , 2018 , 190, E771-E772	3.5	

46	A comparison of mechanisms for setting generic drug prices in Canada. <i>Journal of Generic Medicines</i> , 2017 , 13, 19-27	0.2	2
45	Sustainable Financing of Innovative Therapies: A Review of Approaches. <i>Pharmacoeconomics</i> , 2016 , 34, 971-80	4.4	12
44	Price-cap Regulation, Uncertainty and the Price Evolution of New Pharmaceuticals. <i>Health Economics (United Kingdom)</i> , 2015 , 24, 966-77	2.4	12
43	Fair pricing of "old" orphan drugs: considerations for Canada's orphan drug policy. <i>Cmaj</i> , 2015 , 187, 422-425	3.5	8
42	Newton's First Law as Applied to Pharmacies: Why Entry Order Matters for Generics. <i>International Journal of the Economics of Business</i> , 2015 , 22, 201-217	0.9	3
41	Generic drugs in Canada: an examination of tiered pricing. <i>Cmaj</i> , 2015 , 187, 1033-1034	3.5	2
40	Delays in the submission of new drugs in Canada. <i>Cmaj</i> , 2015 , 187, E47-E51	3.5	11
39	Canada's New Generic Pricing Policy: A Reasoned Approach to a Challenging Problem. <i>Healthcare Policy</i> , 2015 , 11, 10-4	1.1	3
38	The path of least resistance: paying for antibiotics in non-human uses. <i>Health Policy</i> , 2014 , 118, 264-70	3.2	4
37	Synthetic biology: ensuring the greatest global value. <i>Systems and Synthetic Biology</i> , 2013 , 7, 99-105		7
36	Funding innovation for treatment for rare diseases: adopting a cost-based yardstick approach. <i>Orphanet Journal of Rare Diseases</i> , 2013 , 8, 180	4.2	22
35	Preserving antibiotics, rationally. <i>New England Journal of Medicine</i> , 2013 , 369, 2474-6	59.2	96
34	Beyond Benefit Sharing: Steps Towards Realizing the Human Right to Health 2013 , 203-216		1
33	Combating Antibiotic Resistance Through the Health Impact Fund 2013 , 318-338		2
32	Quando las patentes no bastan: Incentivos adicionales para la innovaci3n farmac3utica 2012 , 47-56		
31	New drug development. <i>Lancet, The</i> , 2011 , 377, 901-2	4.0	0
30	Epilogue: New drugs for neglected diseases. <i>Cambridge Quarterly of Healthcare Ethics</i> , 2011 , 20, 329-34	0.9	1
29	When patents are not enough: Supplementary incentives for pharmaceutical innovation 2011 , 39-47		

28	A Critique in Need of Critique. <i>Public Health Ethics</i> , 2010 , 3, 178-185	1.8	7
27	The Health Impact Fund: incentives for improving access to medicines. <i>Lancet, The</i> , 2010 , 375, 166-9	4.0	51
26	The large-scale integration of wind generation: Impacts on price, reliability and dispatchable conventional suppliers. <i>Energy Policy</i> , 2010 , 38, 3837-3846	7.2	55
25	An economic justification for open access to essential medicine patents in developing countries. <i>Journal of Law, Medicine and Ethics</i> , 2009 , 37, 184-208	1.2	52
24	Notes on value for money in healthcare. <i>HealthcarePapers</i> , 2009 , 9, 32-5; discussion 52-5	0.7	
23	Preliminary Injunctions and Damage Rules in Patent Law. <i>Journal of Economics and Management Strategy</i> , 2007 , 16, 385-405	1.9	6
22	The Role of Local Depositors in Controlling Expenses in Small-Scale Financial Intermediation: An Empirical Analysis. <i>Economica</i> , 2007 , 74, 713-735	1.2	9
21	How parallel trade affects drug policies and prices in Canada and the United States. <i>American Journal of Law and Medicine</i> , 2006 , 32, 193-217	0.5	6
20	Comment on "The economics of follow-on drug research and development: trends in entry rates and the timing of development". <i>Pharmacoeconomics</i> , 2005 , 23, 1187-92; discussion 1193-202	4.4	10
19	Governance of electricity transmission systems. <i>Energy Economics</i> , 2005 , 27, 237-255	8.3	8
18	How do Brands Down Generics Affect Pharmaceutical Prices?. <i>Review of Industrial Organization</i> , 2005 , 27, 329-350	1	17
17	Microfinance and Famine: The Irish Loan Funds during the Great Famine. <i>World Development</i> , 2004 , 32, 1509-1523	5.5	17
16	Competition policy in open economies. <i>International Economic Journal</i> , 2004 , 18, 179-193	0.8	2
15	How cheap are Canada's drugs really?. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2004 , 7, 215-6	3.4	3
14	An Irish Working Class: Explorations in Political Economy and Hegemony, 1800-1950. By Marilyn Silverman (Toronto, University of Toronto Press, 2001) 566 pp. \$85.00. <i>Journal of Interdisciplinary History</i> , 2003 , 33, 469-470	0	
13	Industrial Concentration, Output, and Trade: An Empirical Exploration. <i>Review of Industrial Organization</i> , 2003 , 22, 103-119	1	8
12	The Anti-Competitive Effects of Brand-Controlled "Pseudo-Generics" in the Canadian Pharmaceutical Market. <i>Canadian Public Policy/Analyse De Politiques</i> , 2003 , 29, 21	2.5	29
11	The importance of being first: evidence from Canadian generic pharmaceuticals. <i>Health Economics (United Kingdom)</i> , 2002 , 11, 723-34	2.4	53

10	Strategic Implications of Learning by Doing. <i>International Journal of the Economics of Business</i> , 2002 , 9, 157-174	0.9	8
9	The link between publicly funded health care and compulsory licensing. <i>Cmaj</i> , 2002 , 167, 765-6	3.5	
8	The life-cycle of a microfinance institution: the Irish loan funds. <i>Journal of Economic Behavior and Organization</i> , 2001 , 46, 291-311	1.6	35
7	Co-authorship and the output of academic economists. <i>Labour Economics</i> , 2001 , 8, 503-530	1.4	109
6	A contractual approach to the gray market. <i>International Review of Law and Economics</i> , 1999 , 19, 1-21	0.8	35
5	Microcredit: What can we learn from the past?. <i>World Development</i> , 1998 , 26, 1875-1891	5.5	73
4	Microcredit in Prefamine Ireland. <i>Explorations in Economic History</i> , 1998 , 35, 347-380	1.3	28
3	Drugs for Neglected Diseases: New Incentives for Innovation75-90		3
2	Microcredit in Pre-Famine Ireland. <i>SSRN Electronic Journal</i> ,	1	1
1	Combating Antibiotic Resistance Through the Health Impact Fund. <i>SSRN Electronic Journal</i> ,	1	5